8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study)

Anne Boerekamps; Thomas Vanwolleghem; M van der Valk; GE van den Berk; M van Kasteren; D Posthouwer; ASM Dofferhoff; B van Hoek; D Ramsoekh; J Koopsen; J Schinkel; E Florence; JE Arends; Bart Rijnders

doi:10.1016/j.jhep.2018.10.032

8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study)

Anne Boerekamps
, Thomas Vanwolleghem
, M van der Valk
, GE van den Berk
, M van Kasteren
, D Posthouwer
, ASM Dofferhoff
, B van Hoek
, D Ramsoekh
, J Koopsen
, J Schinkel
, E Florence
, JE Arends
, Bart Rijnders

Research output: Contribution to journal › Article › Academic › peer-review

5 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	554-557
Number of pages	4
Journal	Journal of Hepatology
Volume	70
Issue number	3
DOIs	https://doi.org/10.1016/j.jhep.2018.10.032
Publication status	Published - 2019

Research programs

EMC MM-04-20-02-A

Access to Document

10.1016/j.jhep.2018.10.032

http://hdl.handle.net/1765/115183

Cite this

Boerekamps, A., Vanwolleghem, T., van der Valk, M., van den Berk, GE., van Kasteren, M., Posthouwer, D., Dofferhoff, ASM., van Hoek, B., Ramsoekh, D., Koopsen, J., Schinkel, J., Florence, E., Arends, JE., & Rijnders, B. (2019). 8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study). Journal of Hepatology, 70(3), 554-557. https://doi.org/10.1016/j.jhep.2018.10.032

@article{3e24c7c840d844f3ac55e99c03a4fcd0,

title = "8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study)",

author = "Anne Boerekamps and Thomas Vanwolleghem and \{van der Valk\}, M and \{van den Berk\}, GE and \{van Kasteren\}, M and D Posthouwer and ASM Dofferhoff and \{van Hoek\}, B and D Ramsoekh and J Koopsen and J Schinkel and E Florence and JE Arends and Bart Rijnders",

year = "2019",

doi = "10.1016/j.jhep.2018.10.032",

language = "Undefined/Unknown",

volume = "70",

pages = "554--557",

journal = "Journal of Hepatology",

issn = "0168-8278",

publisher = "Elsevier",

number = "3",

}

Boerekamps, A, Vanwolleghem, T, van der Valk, M, van den Berk, GE, van Kasteren, M, Posthouwer, D, Dofferhoff, ASM, van Hoek, B, Ramsoekh, D, Koopsen, J, Schinkel, J, Florence, E, Arends, JE & Rijnders, B 2019, '8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study)', Journal of Hepatology, vol. 70, no. 3, pp. 554-557. https://doi.org/10.1016/j.jhep.2018.10.032

TY - JOUR

T1 - 8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study)

AU - Boerekamps, Anne

AU - Vanwolleghem, Thomas

AU - van der Valk, M

AU - van den Berk, GE

AU - van Kasteren, M

AU - Posthouwer, D

AU - Dofferhoff, ASM

AU - van Hoek, B

AU - Ramsoekh, D

AU - Koopsen, J

AU - Schinkel, J

AU - Florence, E

AU - Arends, JE

AU - Rijnders, Bart

PY - 2019

Y1 - 2019

U2 - 10.1016/j.jhep.2018.10.032

DO - 10.1016/j.jhep.2018.10.032

M3 - Article

C2 - 30527953

SN - 0168-8278

VL - 70

SP - 554

EP - 557

JO - Journal of Hepatology

JF - Journal of Hepatology

IS - 3

ER -